Fernando Alarid-Escudero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/36483/publications.pdf

Version: 2024-02-01

55 papers 1,083

394421 19 h-index 454955 30 g-index

64 all docs 64
docs citations

64 times ranked 1549 citing authors

#	Article	IF	CITATIONS
1	Modeling the Costâ€Effectiveness of Doula Care Associated with Reductions in Preterm Birth and Cesarean Delivery. Birth, 2016, 43, 20-27.	2.2	111
2	Microsimulation Modeling for Health Decision Sciences Using R: A Tutorial. Medical Decision Making, 2018, 38, 400-422.	2.4	85
3	The Household Secondary Attack Rate of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Rapid Review. Clinical Infectious Diseases, 2021, 73, S138-S145.	5.8	82
4	An Overview of R in Health Decision Sciences. Medical Decision Making, 2017, 37, 735-746.	2.4	73
5	Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods. Value in Health, 2020, 23, 734-742.	0.3	51
6	Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests. Journal of the National Cancer Institute, 2021, 113, 154-161.	6.3	46
7	A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer. European Urology Oncology, 2019, 2, 649-655.	5.4	45
8	Estimating the Natural History of Cervical Carcinogenesis Using Simulation Models: A CISNET Comparative Analysis. Journal of the National Cancer Institute, 2020, 112, 955-963.	6.3	37
9	Covid-19 Vaccine Acceptance in California State Prisons. New England Journal of Medicine, 2021, 385, 374-376.	27.0	37
10	COVID-19 in the California State Prison System: an Observational Study of Decarceration, Ongoing Risks, and Risk Factors. Journal of General Internal Medicine, 2021, 36, 3096-3102.	2.6	37
11	A Gaussian Approximation Approach for Value of Information Analysis. Medical Decision Making, 2018, 38, 174-188.	2.4	36
12	Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis. Journal of Urology, 2018, 200, 1215-1220.	0.4	36
13	Outbreaks of COVID-19 variants in US prisons: a mathematical modelling analysis of vaccination and reopening policies. Lancet Public Health, The, 2021, 6, e760-e770.	10.0	35
14	Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. European Urology, 2019, 75, 910-917.	1.9	34
15	A Need for Change! A Coding Framework for Improving Transparency in Decision Modeling. Pharmacoeconomics, 2019, 37, 1329-1339.	3.3	28
16	Estimated Quality of Life and Economic Outcomes Associated With 12 Cervical Cancer Screening Strategies. JAMA Internal Medicine, 2019, 179, 867.	5.1	28
17	Calculating the Expected Value of Sample Information in Practice: Considerations from 3 Case Studies. Medical Decision Making, 2020, 40, 314-326.	2.4	28
18	"Time Traveling Is Just Too Dangerous―but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier. Value in Health, 2019, 22, 611-618.	0.3	22

#	Article	IF	Citations
19	Nonidentifiability in Model Calibration and Implications for Medical Decision Making. Medical Decision Making, 2018, 38, 810-821.	2.4	19
20	Midwifeâ€led care and obstetricianâ€led care for lowâ€risk pregnancies: A cost comparison. Birth, 2020, 47, 57-66.	2.2	19
21	Cost-effectiveness of prevention and early detection of gastric cancer in Western countries. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2021, 50-51, 101735.	2.4	18
22	Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Among Incarcerated People in California State Prisons: Retrospective Cohort Study. Clinical Infectious Diseases, 2022, 75, e838-e845.	5.8	16
23	Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2710-2718.	2.5	14
24	A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management. Value in Health, 2019, 22, 1102-1110.	0.3	12
25	Force of infection ofHelicobacter pyloriin Mexico: evidence from a national survey using a hierarchical Bayesian model. Epidemiology and Infection, 2018, 146, 961-969.	2.1	10
26	Trade-offs Between Efficacy and Cardiac Toxicity of Adjuvant Chemotherapy in Early-Stage Breast Cancer Patients: Do Competing Risks Matter?. Breast Journal, 2017, 23, 401-409.	1.0	9
27	Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis. Pharmacoeconomics, 2017, 35, 1073-1085.	3.3	9
28	Cost-effectiveness analysis of a multidisciplinary health-care model for patients with type-2 diabetes implemented in the public sector in Mexico: A quasi-experimental, retrospective evaluation. Diabetes Research and Clinical Practice, 2020, 167, 108336.	2.8	8
29	BayCANN: Streamlining Bayesian Calibration With Artificial Neural Network Metamodeling. Frontiers in Physiology, 2021, 12, 662314.	2.8	8
30	An Introductory Tutorial on Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example. Medical Decision Making, 2023, 43, 3-20.	2.4	8
31	The Curve of Optimal Sample Size (COSS): A Graphical Representation of the Optimal Sample Size from a Value of Information Analysis. Pharmacoeconomics, 2019, 37, 871-877.	3.3	6
32	A Multidimensional Array Representation of State-Transition Model Dynamics. Medical Decision Making, 2020, 40, 242-248.	2.4	6
33	Potential Bias Associated with Modeling the Effectiveness of Healthcare Interventions in Reducing Mortality Using an Overall Hazard Ratio. Pharmacoeconomics, 2020, 38, 285-296.	3.3	4
34	Age-specific rates of onset of cannabis use in Mexico. Addictive Behaviors, 2021, 122, 107038.	3.0	4
35	Análisis de costo-beneficio: prevención del VIH/sida en migrantes en Centroamérica. Salud Publica De Mexico, 0, 55, 23.	0.4	4
36	Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison. Medical Decision Making, 2022, 42, 956-968.	2.4	4

#	Article	IF	CITATIONS
37	Validation of Microsimulation Models Used for Population Health Policy. , 2020, , 227-240.		3
38	CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis. Value in Health, 2022, 25, 409-418.	0.3	3
39	A Kinked Health Insurance Market: Employer-Sponsored Insurance under the Cadillac Tax. American Journal of Health Economics, 2017, 3, 455-476.	3.0	2
40	Revisiting assumptions about age-based mixing representations in mathematical models of sexually transmitted infections. Vaccine, 2018, 36, 5572-5579.	3.8	2
41	Discussing Cervical Cancer Screening Options: Outcomes to Guide Conversations Between Patients and Providers. MDM Policy and Practice, 2020, 5, 238146832095240.	0.9	2
42	Dependence of COVID-19 Policies on End-of-Year Holiday Contacts in Mexico City Metropolitan Area: A Modeling Study. MDM Policy and Practice, 2021, 6, 238146832110492.	0.9	2
43	Registro de señales de EEG para aplicaciones de Interfaz Cerebro Computadora (ICC) basado en Potenciales Evocados Visuales de Estado Estacionario (PEVEE). IFMBE Proceedings, 2007, , 87-90.	0.3	1
44	92 – Comparing the Cost-Effectiveness of New Colorectal Cancer Screening Tests. Gastroenterology, 2019, 156, S-21.	1.3	1
45	MP73-07 INTRAVESICAL CHEMOTHERAPY FOR LOW GRADE BLADDER CANCER: A COST ANALYSIS. Journal of Urology, 2020, 203, .	0.4	1
46	Retention in Care, Mortality, Loss-to-Follow-Up, and Viral Suppression among Antiretroviral Treatment-NaÃ-ve and Experienced Persons Participating in a Nationally Representative HIV Pre-Treatment Drug Resistance Survey in Mexico. Pathogens, 2021, 10, 1569.	2.8	1
47	Characterization and Valuation of the Uncertainty of Calibrated Parameters in Microsimulation Decision Models. Frontiers in Physiology, 2022, 13, .	2.8	1
48	Calibration of Piecewise Markov Models Using a Change-Point Analysis Through an Iterative Convex Optimization Algorithm. Value in Health, 2015, 18, A814.	0.3	0
49	Force Of Infection Of Helicobacter Pylori In Mexico: Evidence From A National Survey. Value in Health, 2017, 20, A856.	0.3	0
50	Opportunity Cost Of Non-Rigorous Or Non-Transferable Research: Implications For Cost-Effectiveness Analysis. Value in Health, 2017, 20, A863.	0.3	0
51	Towards a Public Health Approach to Homicides in Mexico. SSRN Electronic Journal, 0, , .	0.4	0
52	Prioritizing Research Informing Antibiotic Prophylaxis Guidelines for Knee Arthroplasty Patients. JDR Clinical and Translational Research, 2021, , 238008442110202.	1.9	0
53	MP17-11 ACTIVE SURVEILLANCE FOLLOW-UP STRATEGIES: A COST-EFFECTIVENESS ANALYSIS. Journal of Urology, 2018, 199, .	0.4	0
54	How Do COVID-19 Policy Options Depend on End-of-Year Holiday Contacts in Mexico City Metropolitan Area? A Modeling Study. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	CITATIONS
55	The Cost-Effectiveness of Non-Drug Interventions That Reduce Nursing Home Admissions for People With Dementia. Innovation in Aging, 2021, 5, 227-227.	0.1	0